Hedging on Hype
Four major pharmaceutical rivals—Pfizer, AstraZeneca, Merck, and Teva—formed a joint venture called AION Labs in 2020 to explore AI applications in drug discovery. The collaboration allowed these competitors to share the high costs and risks associated with testing emerging AI technologies.
Why it matters
This unique alliance demonstrates how traditional industry competitors are increasingly pooling resources to navigate the high-stakes integration of AI into R&D processes.
How Four Pharma Rivals Used One Venture Studio to Test-Drive Every AI Trend of the Decade
Pfizer, AstraZeneca, Merck, and Teva are unlikely bedfellows. They chase the same diseases, the same indications, and compete head to head for market share across a long list of products. Getting any two of them to share a lab bench would be strange. Getting all four to co-found and co-own the same company should be impossible.
Yet in 2020, in Israel of all places, they did exactly that, forging an alliance to test the technology that has since become the inescapable front line of nearly every story in this industry: AI.
“If you ask me today, I don’t know if AION Labs would have been established,” says Sharon Gour Arie, COO for the venture studio those four rivals built. “Because AI today is more competitive for them. They’re doing so much internally.”
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in